InvestorsHub Logo
Followers 5
Posts 1278
Boards Moderated 0
Alias Born 04/15/2019

Re: None

Friday, 03/05/2021 8:30:31 AM

Friday, March 05, 2021 8:30:31 AM

Post# of 3353
BCLI: AWAITING BRAINSTORM’S DECISION ON NUROWN® BLA FILING…

https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2021/BCLI-Awaiting-BrainStorms-Decision-on-NurOwn-BLA-Filing-ARTICLE/default.aspx

We’re in a “wait and see” mode regarding the future of NurOwn in ALS as the company continues to gather as much information as possible regarding a potential BLA filing. While we wait for updated guidance from the company, we remind investors that results from the Phase 2 clinical trial of NurOwn in progressive MS should be reported by the end of the first quarter of 2021. Our valuation remains at $10 per share.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BCLI News